Gadolinium decreases inflammation related to myocardial ischemia and reperfusion injury

Jennifer L Strande1, Kasi V Routhu, Anna Hsu

  • 1Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. jstrande@mcw.edu.

Insights

Gadolinium chloride (GdCl3) reduces inflammation and protects the heart from ischemia and reperfusion injury by decreasing circulating monocytes and neutrophils, and their infiltration into the myocardium. This suggests GdCl3 may be a novel treatment for reducing reperfusion injury.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Ischemia and reperfusion (I/R) injury is a significant clinical problem.
  • Neutrophils and macrophages are key inflammatory cells contributing to I/R injury.
  • Gadolinium chloride (GdCl3) has shown potential in protecting the myocardium against I/R injury.

Purpose of the Study:

  • To investigate the protective mechanisms of GdCl3 against I/R injury.
  • To determine the impact of GdCl3 on leukocyte counts, inflammatory cytokine secretion, and myocardial infiltration.
  • To assess GdCl3's effect on monocyte and neutrophil activity during I/R.

Main Methods:

  • Rats were treated with GdCl3 or saline before inducing regional ischemia and reperfusion.
  • Blood and heart tissues were collected for analysis of leukocyte counts, cytokine levels, and inflammatory markers (MPO, ANAE).
  • Measurements included circulating leukocyte counts, serum and myocardial cytokine levels, and tissue MPO and ANAE activity.

Main Results:

  • GdCl3 significantly decreased circulating monocytes and neutrophils during reperfusion.
  • GdCl3 reduced myocardial myeloperoxidase (MPO) and alpha-naphthyl acetate esterase (ANAE) activity, indicating decreased neutrophil and monocyte infiltration.
  • GdCl3 lowered myocardial levels of macrophage-secreted cytokines, GM-CSF and IL-1, but not IL-8.

Conclusions:

  • GdCl3 treatment effectively reduces inflammation associated with I/R injury.
  • GdCl3 appears to inhibit monocyte and neutrophil migration and activation in the myocardium.
  • GdCl3 represents a potential novel therapeutic agent for mitigating ischemia and reperfusion injury.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System IV: CMRI01:21

Imaging Studies for Cardiovascular System IV: CMRI

Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...